−6.56USD
−133.82 MUSD
79.20 MUSD
19.65 M
About Enanta Pharmaceuticals, Inc.
Sector
CEO
Jay R. Luly
Headquarters
Watertown
Website
Employees (FY)
145
ISIN
US29251M1062
FIGI
BBG001V9NSB4
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ENTA is 13.23 USD — it has decreased by 5.50% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Enanta Pharmaceuticals, Inc. stocks are traded under the ticker ENTA.
Enanta Pharmaceuticals, Inc. is going to release the next earnings report on May 6, 2024. Keep track of upcoming events with our Earnings Calendar.
ENTA stock is 5.90% volatile and has beta coefficient of 1.15. Check out the list of the most volatile stocks — is Enanta Pharmaceuticals, Inc. there?
One year price forecast for Enanta Pharmaceuticals, Inc. has a max estimate of 35.00 USD and a min estimate of 11.00 USD.
ENTA earnings for the last quarter are −1.33 USD per share, whereas the estimation was −2.12 USD resulting in a 37.39% surprise. The estimated earnings for the next quarter are −1.23 USD per share. See more details about Enanta Pharmaceuticals, Inc. earnings.
Enanta Pharmaceuticals, Inc. revenue for the last quarter amounts to 18.93 M USD despite the estimated figure of 17.49 M USD. In the next quarter revenue is expected to reach 21.95 M USD.
Yes, you can track Enanta Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
ENTA stock has fallen by 21.01% compared to the previous week, the month change is a 1.78% fall, over the last year Enanta Pharmaceuticals, Inc. has showed a 64.41% decrease.
ENTA net income for the last quarter is −33.41 M USD, while the quarter before that showed −28.11 M USD of net income which accounts for −18.86% change. Track more Enanta Pharmaceuticals, Inc. financial stats to get the full picture.
Today Enanta Pharmaceuticals, Inc. has the market capitalization of 279.89 M, it has increased by 0.06% over the last week.
No, ENTA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ENTA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Enanta Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 145.00 employees. See our rating of the largest employees — is Enanta Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Enanta Pharmaceuticals, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Enanta Pharmaceuticals, Inc. stock shows the sell signal. See more of Enanta Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Enanta Pharmaceuticals, Inc. future price: according to them, ENTA price has a max estimate of 35.00 USD and a min estimate of 11.00 USD. Read a more detailed Enanta Pharmaceuticals, Inc. forecast: see what analysts think of Enanta Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Enanta Pharmaceuticals, Inc. EBITDA is −139.58 M USD, and current EBITDA margin is −170.24%. See more stats in Enanta Pharmaceuticals, Inc. financial statements.